Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Troglitazone].

¹Department of Internal Medicine, University of Teikyo.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|March 9, 2000

Summary

This summary is machine-generated.

Troglitazone effectively lowers blood glucose in type 2 diabetes patients who did not respond to sulfonylureas. This oral therapy offers a new option before insulin treatment, with a low risk of hypoglycemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A mechanical coil insertion system for endovascular coil embolization of intracranial aneurysms.

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences·2013

Same author

An algebraic description of painted digital pictures.

IEEE transactions on pattern analysis and machine intelligence·2012

Same author

Esophageal atresia with double tracheoesophageal fistula--a case report and review of the literature.

European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie·2005

Same author

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2005

Same author

Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia.

Diabetes, obesity & metabolism·2003

Same author

Effects of omega-3 fatty acids in rat allogenic small intestinal transplantation.

Pediatric surgery international·2003

Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019

See all related articles

Area of Science:

Endocrinology
Metabolic Diseases

Background:

Sulfonylurea therapy failure in type 2 diabetes necessitates alternative treatments.
Troglitazone presents a potential therapeutic option for managing hyperglycemia.

Purpose of the Study:

To evaluate the efficacy of troglitazone in type 2 diabetes patients with sulfonylurea failure.
To explore troglitazone's mechanism of action and its role in glycemic control.

Main Methods:

Clinical assessment of glycemic control in patients treated with troglitazone.
Analysis of troglitazone's pharmacokinetic and pharmacodynamic properties.

Main Results:

Troglitazone demonstrated significant reductions in fasting plasma glucose.
Good responders to troglitazone were identified among patients with prior sulfonylurea failure.

Related Experiment Videos

The drug's prolonged action, potentially linked to adipose tissue effects and reduced hepatic glucose output, contributes to its efficacy.

Conclusions:

Troglitazone offers a valuable oral therapeutic approach for type 2 diabetes patients experiencing sulfonylurea failure, serving as an alternative before initiating insulin therapy.
The low incidence of hypoglycemia with troglitazone allows for its safe use in maintaining euglycemia and preventing recurrent hyperglycemia.